id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-3326-0038,FDA,FDA-2015-N-3326,Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments,Notice,Request for Comments,2021-09-22T04:00:00Z,2021,9,2021-09-22T04:00:00Z,2021-12-03T04:59:59Z,2021-12-04T02:00:40Z,2021-20432,0,0,0900006484d9bb68